Figure S4 from The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895366.v1

2023-01-01

Abstract:Figure S4 shows taht PHACTR2-AS1 depletion induced genome instability

What problem does this paper attempt to address?

Figure S7 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Zhaodong Xi,Qi Lei,Yenan Fu,Peng Wang,Wei Zhao,J. Du,Jing Zhang,Jun Zhan,Yunling Wang,Weiguo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895357.v1

2023-01-01

Abstract:Figure S7 shows the PHACTR2-AS1 expression in human tumor tissues.
Figure S2 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895372.v1

2023-01-01

Abstract:Figure S2 shows that PHACTR2-AS1 inhibits pre-rRNA.
The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.can-19-3326

IF: 11.2

2020-01-01

Cancer Research

Abstract:Aberrant activation of histone methyltransferase EZH2 and ribosome synthesis strongly associate with cancer development and progression. We previously found that EZH2 regulates RNA polymerase III-transcribed 5S ribosomal RNA gene transcription. However, whether EZH2 regulates ribosome synthesis is still unknown. Here, we report that EZH2 promotes ribosome synthesis by targeting and silencing a long noncoding RNA PHACTR2-AS1. PHACTR2-AS1 directly bound ribosome DNA genes and recruited histone methyltransferase SUV39H1, which in turn triggered H3K9 methylation of these genes. Depletion of PHACTR2-AS1 resulted in hyperactivation of ribosome synthesis and instability of ribosomal DNA, which promoted cancer cell proliferation and metastasis. Administration of PHACTR2-AS1-30nt-RNA, which binds to SUV39H1, effectively inhibited breast cancer growth and lung metastasis in mice. PHACTR2-AS1 was downregulated in breast cancer patients, where lower PHACTR2-AS1 expression promoted breast cancer development and correlated with poor patient outcome. Taken together, we demonstrate that PHACTR2-AS1 maintains a H3K9 methylation-marked silent state of ribosomal DNA genes, comprising a regulatory axis that controls breast cancer growth and metastasis. SIGNIFICANCE: These findings reveal that EZH2 mediates ribosomal DNA stability via silencing of PHACTR2-AS1, representing a potential therapeutic target to control breast cancer growth and metastasis.
Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Yong Chen,Dongmei Wang,Zhen Guo,Jun Zhao,Bing Wu,Hui Deng,Ti Zhou,Hongjun Xiang,Fei Gao,Xue Yu,Jian Liao,Tarsha Ward,Peng Xia,Chibuzo Emenari,Xia Ding,Winston Thompson,Kelong Ma,Jingde Zhu,Felix Aikhionbare,Kefen Dou,Shi-Yuan Cheng,Xuebiao Yao

DOI: https://doi.org/10.1158/0008-5472.22387211

2023-01-01

Abstract:Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418202.v1

2023-01-01

Abstract:RING1 binds to p53 in vivo and in vitro, and affects the ubiqutination level of p53
Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Yong Chen,Dongmei Wang,Zhen Guo,Jun Zhao,Bing Wu,Hui Deng,Ti Zhou,Hongjun Xiang,Fei Gao,Xue Yu,Jian Liao,Tarsha Ward,Peng Xia,Chibuzo Emenari,Xia Ding,Winston Thompson,Kelong Ma,Jingde Zhu,Felix Aikhionbare,Kefen Dou,Shi-Yuan Cheng,Xuebiao Yao

DOI: https://doi.org/10.1158/0008-5472.can-09-4683

IF: 11.2

2011-01-01

Cancer Research

Abstract:AbstractDuring progression of hepatocellular carcinoma, multiple genetic and epigenetic alterations act to posttranslationally modulate the function of proteins that promote cancer invasion and metastasis. To define such abnormalities that contribute to liver cancer metastasis, we carried out a proteomic comparison of primary hepatocellular carcinoma and samples of intravascular thrombi from the same patient. Mass spectrometric analyses of the liver cancer samples revealed a series of acidic phospho-isotypes associated with the intravascular thrombi samples. In particular, we found that Thr567 hyperphosphorylation of the cytoskeletal protein ezrin was tightly correlated to an invasive phenotype of clinical hepatocellular carcinomas and to poor outcomes in tumor xenograft assays. Using phospho-mimicking mutants, we showed that ezrin phosphorylation at Thr567 promoted in vitro invasion by hepatocarcinoma cells. Phospho-mimicking mutant ezrinT567D, but not the nonphosphorylatable mutant ezrinT567A, stimulated formation of membrane ruffles, suggesting that Thr567 phosphorylation promotes cytoskeletal-membrane remodeling. Importantly, inhibition of Rho kinase, either by Y27632 or RNA interference, resulted in inhibition of Thr567 phosphorylation and a blockade to cell invasion, implicating Rho kinase-ezrin signaling in hepatocellular carcinoma cell invasion. Our findings suggest a strategy to reduce liver tumor metastasis by blocking Rho kinase-mediated phosphorylation of ezrin. Cancer Res; 71(5); 1721–9. ©2011 AACR.
Figure S5 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418190.v1

2023-01-01

Abstract:<p>Knockdown of RING1 suppresses cancer cell migration and inhibits tumor growth in vivo</p>
Figure S6 from the E3 Ligase RING1 Targets P53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418187

2023-01-01

Abstract:p53 exerts little effect on RING1 expression and the genetic alterations of p53 and RING1
Figure S1 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Jiajia Shen,Pengyu Li,Xuejing Shao,Yang Yang,Xiujun Liu,Min Feng,Qiang Yu,Ronggui Hu,Zhen Wang

DOI: https://doi.org/10.1158/0008-5472.22418205

2023-01-01

Abstract:Efficiency of RING1 knockdown and its effect on the transcriptional activity of p21
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395233

2023-01-01

Abstract:Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Data from Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

Li Liao,Yin-Ling Zhang,Ling Deng,Chao Chen,Xiao-Yan Ma,Lisa Andriani,Shao-Ying Yang,Shu-Yuan Hu,Fang-Lin Zhang,Zhi-Min Shao,Da-Qiang Li

DOI: https://doi.org/10.1158/0008-5472.22433349

2023-01-01

Abstract:Supplementary figures and tables
ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

Peijing Zhang,Zhenna Xiao,Shouyu Wang,Mutian Zhang,Yongkun Wei,Qinglei Hang,Jongchan Kim,Fan Yao,Cristian Rodriguez-Aguayo,Baochau N Ton,Minjung Lee,Yumeng Wang,Zhicheng Zhou,Liyong Zeng,Xiaoyu Hu,Sarah E Lawhon,Ashley N Siverly,Xiaohua Su,Jia Li,Xiaoping Xie,Xuhong Cheng,Liang-Chiu Liu,Hui-Wen Chang,Shu-Fen Chiang,Gabriel Lopez-Berestein,Anil K Sood,Junjie Chen,M James You,Shao-Cong Sun,Han Liang,Yun Huang,Xianbin Yang,Deqiang Sun,Yutong Sun,Mien-Chie Hung,Li Ma

DOI: https://doi.org/10.1016/j.celrep.2018.03.078

IF: 8.8

2018-01-01

Cell Reports

Abstract:Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2. Depletion of ZRANB1 in breast cancer cells results in EZH2 destabilization and growth inhibition. Systemic delivery of ZRANB1 small interfering RNA (siRNA) leads to marked antitumor and antimetastatic effects in preclinical models of triple-negative breast cancer (TNBC). Intriguingly, a small-molecule inhibitor of ZRANB1 destabilizes EZH2 and inhibits the viability of TNBC cells. In patients with breast cancer, ZRANB1 levels correlate with EZH2 levels and poor survival. These findings suggest the therapeutic potential for targeting the EZH2 deubiquitinase ZRANB1.
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Zhongwei Li,Diandian Wang,Jun Lu,Baiqu Huang,Yibo Wang,Meichen Dong,Dongmei Fan,Hongyuan Li,Yanyan Gao,Pingfu Hou,Minle Li,Hui Liu,Zhen-Qiang Pan,Junnian Zheng,Jin Bai

DOI: https://doi.org/10.1038/s41418-020-00615-9

IF: 12.067

2020-09-07

Cell Death and Differentiation

Abstract:Enhancer of zeste homolog 2 (EZH2), a key histone methyltransferase and EMT inducer, is overexpressed in diverse carcinomas, including breast cancer. However, the molecular mechanisms of EZH2 dysregulation in cancers are still largely unknown. Here, we discover that EZH2 is asymmetrically dimethylated at R342 (meR342-EZH2) by PRMT1. meR342-EZH2 was found to inhibit the CDK1-mediated phosphorylation of EZH2 at T345 and T487, thereby attenuating EZH2 ubiquitylation mediated by the E3 ligase TRAF6. We also demonstrate that meR342-EZH2 resulted in a decrease in EZH2 target gene expression, but an increase in breast cancer cell EMT, invasion and metastasis. Moreover, we confirm the positive correlations among PRMT1, meR342-EZH2 and EZH2 expression in the breast cancer tissues. Finally, we report that high expression levels of meR342-EZH2 predict a poor clinical outcome in breast cancer patients. Our findings may provide a novel diagnostic target and promising therapeutic target for breast cancer metastasis.

cell biology,biochemistry & molecular biology
The deacetylation-phosphorylation regulation of SIRT2-SMC1A axis as a mechanism of antimitotic catastrophe in early tumorigenesis

Fei Yi,Ying Zhang,Zhijun Wang,Zhuo Wang,Ziwei Li,Tingting Zhou,Hongde Xu,Jingwei Liu,Bo Jiang,Xiaoman Li,Liang Wang,Ning Bai,Qiqiang Guo,Yi Guan,Yanling Feng,Zhiyong Mao,Guangjian Fan,Shengping Zhang,Chuangui Wang,Longyue Cao,Brian P O'Rourke,Yang Wang,Yanmei Wu,Boquan Wu,Shilong You,Naijin Zhang,Junlin Guan,Xiaoyu Song,Yingxian Sun,Shi Wei,Liu Cao,Brian P. O’Rourke

DOI: https://doi.org/10.1126/sciadv.abe5518

IF: 13.6

2021-02-26

Science Advances

Abstract:SIRT2-mediated deacetylation of SMC1A promotes its phosphorylation and overcomes the oncogenic stress for tumor cell survival.

multidisciplinary sciences
EZH2 Takes the Stage when BRCA1 Loses.

Lan Wang,Haojie Huang

DOI: https://doi.org/10.4161/cc.26785

2013-01-01

Abstract:Click to increase image sizeClick to decrease image sizeKeywords:: gene silencingepigeneticsEZH2BRCA1cancer therapynon-coding RNAPRC2embryonic stem cellHOTAIRbasal-like breast cancerThis article is related to:
Supplementary Figure 7 from DAZAP1 Phase Separation Regulates Mitochondrial Metabolism to Facilitate Invasion and Metastasis of Oral Squamous Cell Carcinoma

Jiayi Zhang,Zihui Ni,Yu Zhang,Yan Guo,Rundong Zhai,Mengqi Wang,Zizhen Gong,Mengyao Wang,Fanrui Zeng,Ziyue Gu,Qianming Chen,Laikui Liu,Zhiyong Wang,Weiwen Zhu

DOI: https://doi.org/10.1158/0008-5472.27837702

2024-01-01

Abstract:DAZAP1 promotes OSCC progression via phase separation.

Figure S4 from The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S7 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S2 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Figure S5 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S6 from the E3 Ligase RING1 Targets P53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S1 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Data from Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

The deacetylation-phosphorylation regulation of SIRT2-SMC1A axis as a mechanism of antimitotic catastrophe in early tumorigenesis

EZH2 Takes the Stage when BRCA1 Loses.

Supplementary Figure 7 from DAZAP1 Phase Separation Regulates Mitochondrial Metabolism to Facilitate Invasion and Metastasis of Oral Squamous Cell Carcinoma